SSA
VIR icon

Schonfeld Strategic Advisors’s Vir Biotechnology VIR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.32M Buy
+370,128
New +$2.95M 0.02% 621
2025
Q2 		– Sell
-138,127
Closed -$895K – 2573
2025
Q1 		$895K Buy
+138,127
New +$1.23M 0.01% 1335
2024
Q4 		– Sell
-52,276
Closed -$392K – 2417
2024
Q3 		$392K Sell
52,276
-223,485
-81% -$1.94M ﹤0.01% 1537
2024
Q2 		$2.45M Buy
275,761
+253,395
+1,133% +$2.43M 0.02% 820
2024
Q1 		$227K Buy
+22,366
New +$228K ﹤0.01% 1745
2023
Q4 		– Sell
-162,128
Closed -$1.52M – 2249
2023
Q3 		$1.52M Buy
162,128
+138,387
+583% +$1.97M 0.01% 897
2023
Q2 		$582K Buy
+23,741
New +$596K 0.01% 1164
2023
Q1 		– Sell
-24,600
Closed -$623K – 2686
2022
Q4 		$623K Sell
24,600
-47,495
-66% -$1.16M 0.01% 1408
2022
Q3 		$1.39M Buy
72,095
+9,795
+16% +$249K 0.01% 1067
2022
Q2 		$1.59M Buy
62,300
+50,313
+420% +$1.17M 0.02% 821
2022
Q1 		$309K Sell
11,987
-9,313
-44% -$276K ﹤0.01% 1680
2021
Q4 		$892K Buy
+21,300
New +$834K 0.01% 991

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Schonfeld Strategic Advisors's VIR Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Vir Biotechnology (VIR) in Q1 2026: 370,128 shares worth $3.32M. The stake represents 0.02% of the portfolio and ranks #621 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in VIR as recently as Q1 2025.

Schonfeld Strategic Advisors first reported a position in VIR in Q4 2021 and has held it in 12 quarters since. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Schonfeld Strategic Advisors held 370,128 shares of Vir Biotechnology worth $3.32M as of Q1 2026.
  • Vir Biotechnology was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Vir Biotechnology made up 0.02% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #621 holding.
  • Schonfeld Strategic Advisors first reported a position in Vir Biotechnology in Q4 2021 and has held it in 12 quarters since.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.